ALLO vs RJF · rev $4.6M vs rev $15.91B
Allogene Therapeutics Inc (ALLO) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
RJF (RJF) common stock.
Latest reported ALLO revenue for 2026-06-30 was $4.6M. Net income was -$85.3M. ALLO currently screens at market cap $258.1M.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
ALLO currently screens at market cap $258.1M. RJF currently screens at market cap $0.
Not investment advice. Open the ALLO and RJF stock pages for the full models.
Not investment advice.